FDA Grants Priority Review to CC-486 for the Treatment of Acute Myeloid Leukemia
The FDA granted priority review to a new drug application for CC-486 for the maintenance treatment of adult patients with acute myeloid leukemia based on efficacy and safety results from the pivotal phase III QUAZAR AML-001 study.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Grants | Leukemia | New Drug Applications | Study